Logo image of SCPH

SCPHARMACEUTICALS INC (SCPH) Stock Fundamental Analysis

NASDAQ:SCPH - Nasdaq - US8106481059 - Common Stock - Currency: USD

5.41  -0.11 (-1.99%)

After market: 5.41 0 (0%)

Fundamental Rating

2

SCPH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. SCPH may be in some trouble as it scores bad on both profitability and health. SCPH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SCPH had negative earnings in the past year.
SCPH had a negative operating cash flow in the past year.
SCPH had negative earnings in each of the past 5 years.
SCPH had a negative operating cash flow in each of the past 5 years.
SCPH Yearly Net Income VS EBIT VS OCF VS FCFSCPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -99.80%, SCPH is not doing good in the industry: 74.61% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -99.8%
ROE N/A
ROIC N/A
ROA(3y)-55.62%
ROA(5y)-46.38%
ROE(3y)-279.13%
ROE(5y)-185.24%
ROIC(3y)N/A
ROIC(5y)N/A
SCPH Yearly ROA, ROE, ROICSCPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K 5K

1.3 Margins

With a decent Gross Margin value of 68.92%, SCPH is doing good in the industry, outperforming 76.68% of the companies in the same industry.
SCPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCPH Yearly Profit, Operating, Gross MarginsSCPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

SCPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SCPH has been increased compared to 1 year ago.
The number of shares outstanding for SCPH has been increased compared to 5 years ago.
SCPH has a worse debt/assets ratio than last year.
SCPH Yearly Shares OutstandingSCPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SCPH Yearly Total Debt VS Total AssetsSCPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -5.16, we must say that SCPH is in the distress zone and has some risk of bankruptcy.
SCPH's Altman-Z score of -5.16 is on the low side compared to the rest of the industry. SCPH is outperformed by 61.14% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.16
ROIC/WACCN/A
WACC10.06%
SCPH Yearly LT Debt VS Equity VS FCFSCPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 5.48 indicates that SCPH has no problem at all paying its short term obligations.
The Current ratio of SCPH (5.48) is better than 74.61% of its industry peers.
SCPH has a Quick Ratio of 4.61. This indicates that SCPH is financially healthy and has no problem in meeting its short term obligations.
SCPH has a better Quick ratio (4.61) than 69.95% of its industry peers.
Industry RankSector Rank
Current Ratio 5.48
Quick Ratio 4.61
SCPH Yearly Current Assets VS Current LiabilitesSCPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

SCPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.05%.
Looking at the last year, SCPH shows a very strong growth in Revenue. The Revenue has grown by 138.02%.
EPS 1Y (TTM)-29.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.78%
Revenue 1Y (TTM)138.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%92.59%

3.2 Future

Based on estimates for the next years, SCPH will show a very strong growth in Earnings Per Share. The EPS will grow by 24.25% on average per year.
Based on estimates for the next years, SCPH will show a very strong growth in Revenue. The Revenue will grow by 54.53% on average per year.
EPS Next Y43.9%
EPS Next 2Y35.85%
EPS Next 3Y32.42%
EPS Next 5Y24.25%
Revenue Next Year105.36%
Revenue Next 2Y88.94%
Revenue Next 3Y76.78%
Revenue Next 5Y54.53%

3.3 Evolution

SCPH Yearly Revenue VS EstimatesSCPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
SCPH Yearly EPS VS EstimatesSCPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SCPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCPH Price Earnings VS Forward Price EarningsSCPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCPH Per share dataSCPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as SCPH's earnings are expected to grow with 32.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.85%
EPS Next 3Y32.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SCPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCPHARMACEUTICALS INC

NASDAQ:SCPH (8/5/2025, 8:00:02 PM)

After market: 5.41 0 (0%)

5.41

-0.11 (-1.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners58.37%
Inst Owner Change-1.15%
Ins Owners6.08%
Ins Owner Change-2.89%
Market Cap285.59M
Analysts83.64
Price Target15.91 (194.09%)
Short Float %3.95%
Short Ratio4.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.21%
Min EPS beat(2)-21.73%
Max EPS beat(2)9.3%
EPS beat(4)1
Avg EPS beat(4)-41.15%
Min EPS beat(4)-147.99%
Max EPS beat(4)9.3%
EPS beat(8)4
Avg EPS beat(8)-16.53%
EPS beat(12)7
Avg EPS beat(12)-8.07%
EPS beat(16)11
Avg EPS beat(16)-1.41%
Revenue beat(2)0
Avg Revenue beat(2)-1.17%
Min Revenue beat(2)-1.43%
Max Revenue beat(2)-0.92%
Revenue beat(4)0
Avg Revenue beat(4)-3.07%
Min Revenue beat(4)-9%
Max Revenue beat(4)-0.92%
Revenue beat(8)3
Avg Revenue beat(8)0.62%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.86%
PT rev (3m)2.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.74%
EPS NY rev (1m)-5.13%
EPS NY rev (3m)-6.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.8
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.33
OCFYN/A
SpS0.8
BVpS-0.1
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.8%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.92%
FCFM N/A
ROA(3y)-55.62%
ROA(5y)-46.38%
ROE(3y)-279.13%
ROE(5y)-185.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.48
Quick Ratio 4.61
Altman-Z -5.16
F-Score2
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)23.53%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.78%
EPS Next Y43.9%
EPS Next 2Y35.85%
EPS Next 3Y32.42%
EPS Next 5Y24.25%
Revenue 1Y (TTM)138.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%92.59%
Revenue Next Year105.36%
Revenue Next 2Y88.94%
Revenue Next 3Y76.78%
Revenue Next 5Y54.53%
EBIT growth 1Y-11.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.6%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.13%
OCF growth 3YN/A
OCF growth 5YN/A